Information Provided By:
Fly News Breaks for March 27, 2015
SNY, REGN
Mar 27, 2015 | 14:04 EDT
Argus raised its price target on Regeneron (REGN) after the company and its partner Sanofi (SNY) announced that their cholesterol-lowering drug, Praluent, delivered “robust and consistent” results in a Phase III trial. The firm finds the stock's valuation attractive and keeps a Buy rating on the shares.
News For REGN;SNY From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.